HomeCompareATNX vs BTI

ATNX vs BTI: Dividend Comparison 2026

ATNX yields 984.74% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATNX wins by $16481957.00M in total portfolio value
10 years
ATNX
ATNX
● Live price
984.74%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16481957.04M
Annual income
$13,737,663,418,719.40
Full ATNX calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — ATNX vs BTI

📍 ATNX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATNXBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATNX + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATNX pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATNX
Annual income on $10K today (after 15% tax)
$83,702.61/yr
After 10yr DRIP, annual income (after tax)
$11,677,013,905,911.49/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, ATNX beats the other by $11,677,013,903,542.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATNX + BTI for your $10,000?

ATNX: 50%BTI: 50%
100% BTI50/50100% ATNX
Portfolio after 10yr
$8240978.54M
Annual income
$6,868,831,710,753.02/yr
Blended yield
83.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ATNX
Analyst Ratings
5
Buy
5
Hold
Consensus: Buy
Altman Z
-7.5
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATNX buys
0
BTI buys
0
No recent congressional trades found for ATNX or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATNXBTI
Forward yield984.74%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$16481957.04M$37.7K
Annual income after 10y$13,737,663,418,719.40$2,786.64
Total dividends collected$16271814.37M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ATNX vs BTI ($10,000, DRIP)

YearATNX PortfolioATNX Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$109,174$98,473.66$11,299$598.92+$97.9KATNX
2$1,121,557$1,004,741.08$12,794$703.91+$1.11MATNX
3$10,846,656$9,646,590.10$14,518$829.07+$10.83MATNX
4$98,795,506$87,189,583.88$16,513$978.64+$98.78MATNX
5$847,913,243$742,202,051.48$18,827$1,157.84+$847.89MATNX
6$6,860,496,352$5,953,229,181.85$21,518$1,373.12+$6860.47MATNX
7$52,357,357,343$45,016,626,246.62$24,657$1,632.46+$52357.33MATNX
8$377,100,961,928$321,078,589,571.04$28,329$1,945.74+$377100.93MATNX
9$2,564,760,394,425$2,161,262,365,161.88$32,637$2,325.33+$2564760.36MATNX
10$16,481,957,040,754$13,737,663,418,719.40$37,708$2,786.64+$16481957.00MATNX

ATNX vs BTI: Complete Analysis 2026

ATNXStock

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Full ATNX Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ATNX vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATNX vs SCHDATNX vs JEPIATNX vs OATNX vs KOATNX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.